Citations

Showing 10 of 108104 citations.

Uterine Fibroids and the Risk of Cardiovascular Disease in the Coronary Artery Risk Development in Young Adult Women's Study
Laughlin-Tommaso, Shannon K., Fuchs, Erika , Wellons, Melissa, Lewis, Cora E. , Calderon‐Margalit, Ronit , Schreiner, Pamela J. , Stewart, Elizabeth A.

Mayo Clinic

Journal of Women's Health | November 9, 2018 | Volume: 28 | Issue: 1 | Pages: 46-52

10.1089/jwh.2018.7122 | PMID 30412447 Get It

The Reciprocity between Radiotherapy and Cancer Immunotherapy
Wang, Yifan , Liu, Zhi-Gang, Yuan, Hengfeng , Deng, Weiye , Li, Jing , Huang, Yu-Hui , Kim, Betty Y.S. , Story, Michael D. , Jiang, Wen , Huang, Yuhui , Huang, Yuhui , Jiang, Wen , Kim, Betty Y S

Mayo Clinic

Clinical Cancer Research | November 9, 2018 | Volume: 25 | Issue: 6 | Pages: 1709-1717

10.1158/1078-0432.ccr-18-2581 | PMID 30413527 Get It

Abstract The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.
Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101
Barginear, Myra F., Dueck, Amylou C. , Allred, Jacob B., Bunnell, Craig A. , Cohen, Harvey Jay, Hurria, Arti , Kimmick, Gretchen , Lichtman, Stuart M. , Muss, Hyman B. , Copur, M. Sitiki, Biggs, David D., Ramaswamy, Bhuvaneswari , Lafky, Jacqueline M., Jatoi, Aminah , Dueck, A. C. , Lichtman, Stuart M , Freedman, Rachel A. , Le‐Rademacher, Jennifer , Shulman, Lawrence N. , Copur, M. Sitiki

Mayo Clinic

The Oncologist | November 9, 2018 | Volume: 24 | Issue: 5 | Pages: 617-623

10.1634/theoncologist.2018-0298 | PMID 30409792 Get It

Abstract Purpose A few previous studies report a direct relationship between older age and chemotherapy-induced neuropathy. This study further evaluated this adverse event's age-based risk. Methods CALGB 40101 investigated adjuvant paclitaxel (80 mg/m2 once per week or 175 mg/m2 every 2 weeks) in patients with breast cancer and served as a platform for the current study that investigated age-based differences in neuropathy. Grade 2 or worse neuropathy, as per Common Terminology Criteria for Adverse Events version 4, was the primary endpoint; patients were assessed at baseline, every 6 months for 2 years, and then annually for 15 years. Results Among these 1,881 patients, 230 were 65 years of age or older, 556 were 55–64 years, and 1,095 were younger than 55; 1,226 neuropathy events (commonly grade 1 or 2) were reported in 65% of the cohort. The number of grade 2 or worse events was 63 (27%), 155 (28%), and 266 (24%) within respective age groups (p = .14). In univariate analysis, only motor neuropathy had a higher age-based incidence: 19 (8%), 43 (8%), and 60 (5%), respectively (p = .04); in multivariate analyses, this association was no longer statistically significant. Other endpoints, such as time to onset of neuropathy (time from trial enrollment to neuropathy development) and time to improvement (time from maximal grade sensory neuropathy to a one-category improvement), showed no statistically significant age-based differences. In contrast, obesity was associated with neuropathy, and every 2-week paclitaxel was associated with trends toward neuropathy. Conclusion Although paclitaxel-induced neuropathy is common, older age is not an independent risk factor. Clinical trial identification number. NCT00041119 (CALGB 40101).
Evaluation of the CosmosID Bioinformatics Platform for Prosthetic Joint-Associated Sonicate Fluid Shotgun Metagenomic Data Analysis
Wi, Yu Mi , Thoendel, Matthew , Raval, Yash S. , Greenwood‐Quaintance, Kerryl E. , Jeraldo, Patricio , Patel, Robin , Yan, Qun , Thoendel, Matthew J, Jeraldo, Patricio R , Chia, Nicholas , Patel, Robin , Yan, Qun , Abdel, Matthew P. , Chia, Nicholas , Thoendel, Matthew J , Raval, Yash S.

Mayo Clinic

Journal of Clinical Microbiology | November 9, 2018 | Volume: 57 | Issue: 2 | Pages: No page available

10.1128/jcm.01182-18 | PMID 30429253 Get It

We previously demonstrated that shotgun metagenomic sequencing can detect bacteria in sonicate fluid, providing a diagnosis of prosthetic joint infection (PJI). A limitation of the approach that we used is that data analysis was time-consuming and specialized bioinformatics expertise was required, both of which are barriers to routine clinical use.
High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer
Majumder, Shounak , Philip, N, Takahashi, Naoki , Mara, Kristin C. , Kendrick, Michael L. , Smyrk, Thomas C. , Zhang, Lizhi , Levy, Michael J. , Gleeson, Ferga C. , Petersen, Bret T. , Pearson, Randall K., Topazian, Mark , Vege, Santhi Swaroop , Chari, Suresh T. , Singh Nagpal, Sajan Jiv, Majumder, Shounak , Mara, Kristin C , Takahashi, Naoki , Nagpal, Sajan Jiv Singh , Chari, Suresh T

Mayo Clinic

American Journal of Gastroenterology | November 9, 2018 | Volume: 114 | Issue: 3 | Pages: 524-529

10.1038/s41395-018-0403-2 | PMID 30413822 Get It

BACKGROUND: There is lack of consensus on post-operative surveillance for resected non-invasive intraductal papillary neoplasms (IPMNs). In this study we explored risk factors for subsequent PC in patients with MD-IPMN undergoing partial pancreatectomy. METHODS: We searched the Mayo Clinic surgical pathology database for all cases of resected MD-IPMN between 1997 and 2014. Cases with histologically confirmed main pancreatic duct involvement either isolated or in a mixed pattern with branch-duct involvement were included. Outcomes of PC in the remnant pancreas, and death related to MD-IPMN were assessed with survival analyses (Kaplan–Meier and Cox regression). RESULTS: Among the 179 patients with resected MD-IPMN the incidence of concomitant PC and high-grade dysplasia (HGD) in the resected specimen was 23 and 14%, respectively. The mean duration of follow-up was 4.31 years (range 0.12–13.5 years). Excluding 28 subjects who either underwent initial total pancreatectomy or partial pancreatectomy with surgical margins positive for PC/HGD, the 5-year incidence of subsequent PC was 12%, including 60.6% and 15.6% in those with initial PC and HGD, respectively. The 10-year incidence of PC was 21.2% overall, 60.6% for PC, 38.3% for HGD, and 3.0% for LGD. Risk of subsequent PC was significantly higher for those with initial PC compared with HGD (HR = 4.95, 95% CI: 1.63–15.03, p = 0.005 and for HGD compared with LGD (HR = 11.30, 95% CI: 1.55–82.26, p = 0.017). CONCLUSIONS: Patients with MD-IPMN with PC or HGD undergoing segmental pancreatectomy are at higher risk of subsequent PC and may benefit from post-operative surveillance. The post-operative surveillance intervals in resected MD-IPMNs need to be tailored based on dysplasia grade.
Does external beam radiation therapy to the pelvis portend worse ileal pouch outcomes? An international multi‐institution collaborative study
Spinelli, Antonino , McKenna, Nicholas P. , Hallemeier, Christopher L. , Fleshner, Philip, McKenna, Nicholas P , Spinelli, Antonino , Lightner, Amy L. , Hallemeier, Christopher Leigh

Mayo Clinic

Colorectal Disease | November 9, 2018 | Volume: 21 | Issue: 2 | Pages: 219-225

10.1111/codi.14467 | PMID 30411480 Get It

AbstractAimShort‐term morbidity and long‐term functional outcome of patients with an ileal pouch‐anal anastomosis (IPAA) exposed to pelvic external beam radiation therapy (EBRT) remains unknown. We report the largest series to date regarding the effects of pelvic EBRT on: (i) 30‐day postoperative outcomes; and (ii) long‐term functional outcome following IPAA.MethodA retrospective chart review was conducted of patients who received EBRT before or after IPAA between 1980 and 2017 across three international inflammatory bowel disease referral centres.ResultsNineteen patients were included. Indications for EBRT were rectal adenocarcinoma (n = 13), prostate adenocarcinoma (n = 4) or anal squamous cell carcinoma (ASCC) (n = 2). EBRT was given prior to IPAA in 12 (63%) patients and after IPAA in seven (37%). In EBRT before IPAA, patients had a median of 5 (range: 4–8) daytime bowel movements, 1 (range: 0–5) night‐time bowel movement, no daytime incontinence, and only one patient used pads at a median follow up of 25 (range: 11–163) months; one patient underwent pouch excision 15 months after IPAA. In EBRT after IPAA, patients reported a median of 8 (range: 5–10) daytime and 2 (range: 0–5) night‐time bowel movements, 80% had either daytime or night‐time incontinence and 80% used pads at a median follow up of 90 (range: 25–315) months.ConclusionPelvic EBRT administered prior to IPAA is associated with acceptable long‐term function outcome. However, when pelvic EBRT is given to an IPAA in situ, most patients experience poor long‐term pouch function without pouch failure.
Phrenic motoneuron structural plasticity across models of diaphragm muscle paralysis
Mantilla, Carlos B. , Zhan, Wen‐Zhi, Gransee, Heather M. , Prakash, Y. S. , Sieck, Gary C. , Prakash, Y S , Sieck, Gary , Gransee, Heather M , Mantilla, Carlos B

Mayo Clinic

Journal of Comparative Neurology | November 9, 2018 | Volume: 526 | Issue: 18 | Pages: 2973-2983

10.1002/cne.24503 | PMID 30411341 Get It

AbstractStructural plasticity in motoneurons may be influenced by activation history and motoneuron–muscle fiber interactions. The goal of this study was to examine the morphological adaptations of phrenic motoneurons following imposed motoneuron inactivity while controlling for diaphragm muscle inactivity. Well‐characterized rat models were used including unilateral C2 spinal hemisection (SH; ipsilateral phrenic motoneurons and diaphragm muscle are inactive) and tetrodotoxin phrenic nerve blockade (TTX; ipsilateral diaphragm muscle is paralyzed while phrenic motoneuron activity is preserved). We hypothesized that inactivity of phrenic motoneurons would result in a decrease in motoneuron size, consistent with a homeostatic increase in excitability. Phrenic motoneurons were retrogradely labeled by ipsilateral diaphragm muscle injection of fluorescent dextrans or cholera toxin subunit B. Following 2 weeks of diaphragm muscle paralysis, morphological parameters of labeled ipsilateral phrenic motoneurons were assessed quantitatively using fluorescence confocal microscopy. Compared to controls, phrenic motoneuron somal volumes and surface areas decreased with SH, but increased with TTX. Total phrenic motoneuron surface area was unchanged by SH, but increased with TTX. Dendritic surface area was estimated from primary dendrite diameter using a power equation obtained from three‐dimensional reconstructed phrenic motoneurons. Estimated dendritic surface area was not significantly different between control and SH, but increased with TTX. Similarly, TTX significantly increased total phrenic motoneuron surface area. These results suggest that ipsilateral phrenic motoneuron morphological adaptations are consistent with a normalization of motoneuron excitability following prolonged alterations in motoneuron activity. Phrenic motoneuron structural plasticity is likely more dependent on motoneuron activity (or descending input) than muscle fiber activity.
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients
Fetterly, Gerald, Pitzonka, Laura, Whitworth, Amy, LeVea, Charles , Wilton, John H., Mantione, Krystin , Schihl, Sarah A. , Dy, Grace K. , Iyer, Renuka , Brady, William E., Straubinger, Robert M. , Adjei, Alex A. , Ma, Wen Wee, Wee, Wen , Xie, Hao , Boland, Patrick M. , Tan, Wei

Mayo Clinic

American Journal of Clinical Oncology | November 8, 2018 | Volume: 42 | Issue: 2 | Pages: 184-189

10.1097/coc.0000000000000492 | PMID 30418178 Get It

Objectives: Preclinical studies demonstrated antitumor activity of dovitinib in pancreatic cancer models. This phase Ib study aimed to determine the maximum tolerated dose (MTD) of dovitinib in combination with gemcitabine and capecitabine and to characterize the safety and pharmacokinetic profile in patients with advanced pancreatic and biliary tract cancers and solid malignancies. Materials and Methods: Patients received gemcitabine 1000 mg/m² intravenously on days 1 and 8, capecitabine 1300 mg/m² oral daily from day 1 to 14, and dovitinib oral daily 5 days on and 2 days off, every 21-day cycle. The standard 3+3 dose escalation design was utilized and the study expanded to treat an additional 20 advanced pancreatic and biliary tract cancers patients at MTD. Results: A total of 29 patients were enrolled. One patient experienced dose-limiting grade 3 colitis. Two patients developed clinically significant neuropathy after the first cycle requiring dose reduction. The MTD was not reached and dovitinib 300 mg was declared the recommended dose for expansion. The most frequent grade 2 or worse adverse events were fatigue (45%), neutropenia (41%), thrombocytopenia (34%), anemia (24%), nausea (24%), and palmer-plantar erythrodysaesthesia syndrome (21%). Partial responses were observed in 5 patients. Pharmacokinetic studies showed no drug-drug interaction between dovitinib, capecitabine and gemcitabine. Fibroblast growth factor 23 plasma level increased in 4 of 5 patients during the first cycle of treatment. Conclusions: Dovitinib 300 mg daily is the recommended dose when combined with gemcitabine and capecitabine, achieving clinically relevant plasma concentrations. The study combination demonstrated encouraging efficacy signals in advanced pancreatic cancer.
Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy
Wilson, Eric , Anderson, Karen S.

Mayo Clinic

Expert Review of Proteomics | November 8, 2018 | Volume: 15 | Issue: 12 | Pages: 1065-1077

10.1080/14789450.2018.1545578 | PMID 30408427 Get It

Factors Associated with Immunotherapy Selection in Patients with Advanced Melanoma
Shillington, Alicia C, Macahilig, Cynthia, Diede, Scott J. , Dave, Vaidehi , Harshaw, Qing, Liu, Frank Xiaoqing, Shillington, Alicia C. , Joseph, Richard W. , Shillington, Alicia C

Mayo Clinic

Immunotherapy | November 8, 2018 | Volume: 10 | Issue: 16 | Pages: 1361-1369

10.2217/imt-2018-0150 | PMID 30407098 Get It